Healthcare AI Checklist for Healthcare & Biotech

Start with a narrow problem such as radiology triage, pathology slide classification, adverse event detection, or hit identification in drug discovery. Focused scope reduces validation time and makes it easier to align endpoints with clinical, operational, or translational value.

Specify whether the model supports a radiologist, lab scientist, clinical trial operations team, or care coordinator, and identify exactly when they will use it. Many healthcare AI projects fail because predictions arrive too late or in a format that does not fit EHR, LIS, PACS, or LIMS workflows.

Tie the project to measurable outcomes such as reduced time-to-diagnosis, fewer false negatives, faster compound screening, lower protocol deviation rates, or improved patient throughput. Clear value framing is essential for budget approval, IRB support, and enterprise adoption.

Determine if clinicians or researchers will review outputs before action, or if the system triggers downstream processes automatically. This distinction affects risk classification, oversight requirements, and the level of evidence needed for deployment.

Define minimum performance thresholds such as sensitivity, specificity, PPV, NPV, calibration, and turnaround time based on the intended use. In biotech discovery settings, specify assay enrichment, recall at top-k, or reduction in wet-lab validation burden.

For clinical applications, evaluate whether the solution supports provider efficiency, quality metrics, or reimbursement-linked outcomes. For biotech applications, clarify whether the product will monetize through SaaS, platform licensing, co-development, or milestone-based partnerships.

List structured and unstructured inputs such as EHR data, imaging studies, pathology slides, genomics, proteomics, wearables, assay outputs, and trial data. Assign ownership across compliance, IT, clinical operations, and research teams to prevent access bottlenecks later.

Confirm whether patient consent, trial agreements, and data use agreements allow model training, validation, and commercial deployment. In biotech collaborations, review whether omics datasets and compound libraries can be used for derivative model development.

Implement role-based access, audit logs, encryption at rest and in transit, and documented retention policies for PHI and sensitive research data. Cross-border clinical studies and multinational biobanks often require jurisdiction-specific handling and data minimization controls.

Define how identifiers will be removed or tokenized for imaging, clinical notes, genomic records, and lab datasets. Use documented re-identification risk assessments, especially where longitudinal linkage or rare disease cohorts make anonymization more difficult.

Measure missingness, coding inconsistencies, scanner variability, assay drift, and inter-rater disagreement in labels. In healthcare and biotech, poor labels often come from retrospective chart abstraction, inconsistent pathology review, or changing lab protocols.

Assess whether the data reflects the target care settings, scanner vendors, demographic groups, disease prevalence, and trial populations where the model will be used. Site-specific bias is common in hospital systems and multicenter research programs.

Use reproducible pipelines and dataset versioning so every model result can be traced back to source files, preprocessing steps, and annotation rounds. This is essential for CAPA investigations, regulatory submissions, and scientific reproducibility.

Match the approach to the problem, such as CNNs or vision transformers for imaging, foundation models for clinical text, graph models for molecular structures, or multimodal systems for combined EHR and imaging tasks. Consider latency, interpretability, and compute needs in regulated environments.

Go beyond AUROC by tracking sensitivity at clinically acceptable false positive rates, calibration, subgroup performance, and prospective utility. In drug discovery, include enrichment factor, hit rate improvement, or candidate prioritization accuracy tied to downstream lab validation.

Test across hospitals, lab sites, assay batches, and later time periods to detect overfitting to local practice patterns or instrumentation. External validation is one of the clearest signals that a healthcare AI system may generalize in production.

Evaluate performance by age, sex, race, comorbidity burden, disease stage, scanner type, and care setting where applicable. For biotech, test by assay platform, tissue source, and cohort origin to uncover hidden failure modes before deployment.

Determine whether clinicians need saliency maps, feature attribution, evidence snippets, uncertainty scores, or exemplar retrieval to trust recommendations. For regulated workflows, explanation methods should be tested for consistency and not treated as cosmetic add-ons.

Probe performance on low-quality scans, rare diseases, unusual lab values, incomplete records, and shifted assay conditions. Documenting failure boundaries helps define when the model should abstain or escalate to human review.

Assess whether the product may be treated as SaMD, clinical decision support, or a research-use-only tool depending on jurisdiction and intended use. Early classification shapes documentation, evidence requirements, and commercialization timelines.

Implement controlled documentation, change management, CAPA, design controls, and supplier oversight appropriate for healthcare software and diagnostics. Even research-stage biotech platforms benefit from QMS discipline when moving toward regulated partnerships or clinical use.

Write precise labeling that defines what the model does, what data it expects, who can use it, and when outputs should not be relied upon. Ambiguous intended use language creates downstream problems in legal review, regulatory submissions, and clinical adoption.

Decide whether retrospective validation is sufficient or if silent trials, prospective studies, reader studies, or pragmatic deployment evidence are required. For high-impact workflows, prospective evidence often matters more than incremental retrospective gains.

Confirm when model evaluation, silent deployment, or clinician-facing pilots require IRB review, ethics approval, or data safety monitoring. This is especially important when using live patient data, adaptive models, or intervention-linked recommendations.

Define how performance, incidents, clinician feedback, and drift will be monitored after release. Regulators, enterprise customers, and hospital risk committees increasingly expect a documented surveillance plan for AI-enabled products.

Deliver results through the tools teams already use, such as EHR inboxes, PACS overlays, pathology viewers, trial dashboards, or LIMS interfaces. Adoption increases when users do not have to switch platforms or manually re-enter identifiers.

Define what happens when the model abstains, returns low-confidence output, or the upstream data feed fails. In patient care settings, fallback protocols should default safely to standard clinical workflow without delaying treatment.

Provide role-specific training for physicians, pharmacists, lab managers, data scientists, and trial operators using examples drawn from real cases. Training should cover interpretation limits, override conditions, and documentation expectations.

Capture model inputs, outputs, confidence, latency, version, and user actions in secure logs with retention policies. Monitoring should include drift alerts, failed message routing, and usage analytics by site or department.

Specify who can approve updates, what evidence is required, and how revised models are validated before release. In healthcare and biotech, uncontrolled retraining can break comparability, invalidate documentation, or introduce regulatory risk.

Track real-world indicators such as reduced turnaround time, lower chart review burden, improved trial enrollment efficiency, better assay prioritization, or changes in diagnostic yield. This evidence supports renewals, procurement expansion, and research partnerships.